Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Cisplatin, and Ifosfamide in Advanced Non-Transitional Cell Urothelial Tumors
NCT00002684Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 1995
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, cisplatin and ifosfamide in urothelial carcinoma (UC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Efficacy. Started May 1995; status: completed.
02
Drugs
paclitaxelcisplatinifosfamide
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00002684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002684.